|
| 37885116 | Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to <sup>131</sup> I-MIBG in patients with relapsed/refractory neuroblastoma. | Pediatr Blood Cancer | 2024 |
| 37501549 | Children's Oncology Group's 2023 blueprint for research: Bone tumors. | Pediatr Blood Cancer | 2023 |
| 36305832 | Early Termination of Oncology Clinical Trials in the United States. | Cancer Medicine | 2023 |
| 36302496 | Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. | Int J Radiat Oncol Biol Phys | 2023 |
| 36150094 | Reply to D.J. Benedetti et al. | Journal of Clinical Oncology | 2023 |
| 36316811 | Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. | Pediatric Blood and Cancer | 2023 |
| 37651654 | Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. | J Clin Oncol | 2023 |
| 37908736 | Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction. | | 2023 |
| 37644664 | Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. | | 2023 |
| 37715723 | Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. | | 2023 |
| 37961910 | Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials. | | 2023 |
| 37458162 | Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. | | 2023 |
| 37264747 | A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. | Cancer Med | 2023 |
| 37015036 | Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. | J Clin Oncol | 2023 |
| 37306107 | Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. | Cancer Med | 2023 |
| 36458672 | Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020. | Pediatr Blood Cancer | 2023 |
| 36724417 | Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 36669140 | Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 34933891 | Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Zr-Labeled Anti-PD-L1 Antibody Formats. | | 2022 |
| 36221002 | Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. | Br J Cancer | 2022 |
| 35809374 | Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. | Eur J Cancer | 2022 |
| 35739269 | Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. | Nat Med | 2022 |
| 35427148 | High-Risk Ewing Sarcoma: It Is Time to Break the Ceiling. | Journal of Clinical Oncology | 2022 |
| 35998011 | Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand. | Molecular Pharmaceutics | 2022 |
| 35484995 | <sup>68</sup> Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. | Pediatr Blood Cancer | 2022 |
| 35731997 | Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. | JCO Precision Oncology | 2022 |
| 35417004 | Report of the First International Symposium on NUT Carcinoma. | Clin Cancer Res | 2022 |
| 35863108 | Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2022 |
| 35543076 | Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. | Histopathology | 2022 |
| 36446043 | Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. | JCO Precis Oncol | 2022 |
| 36115869 | An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. | NPJ Precis Oncol | 2022 |
| 32721198 | Exploring political diversity in relation to health and stress, among graduate students in the mental health field. | | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 34673986 | Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. | Radiation Research | 2022 |
| 35235382 | Reply to J.-G. Wang et al. | Journal of Clinical Oncology | 2022 |
| 34850167 | Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. | Neuro Oncol | 2022 |
| 35188340 | Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. | Pediatr Blood Cancer | 2022 |
| 34662499 | Anatomic patterns of relapse and progression following treatment with <sup>131</sup> I-MIBG in relapsed or refractory neuroblastoma. | Pediatr Blood Cancer | 2022 |
| 34814185 | Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. | Pediatrics | 2021 |
| 33751835 | Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. | Cancer Med | 2021 |
| 34171886 | Results of a Brief, Peer-Led Intervention Pilot on Cognitive Escape Among African American Adults Living With HIV, Comorbid Serious Mental Illness, and a History of Adverse Childhood Experiences. | Journal of the Association of Nurses in AIDS Care | 2021 |
| 33852135 | Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. | European Journal of Drug Metabolism and Pharmacokinetics | 2021 |
| 33474828 | Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. | Cancer Med | 2021 |
| 34270348 | Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. | J Clin Oncol | 2021 |
| 34152837 | Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials. | Journal of Clinical Oncology | 2021 |
| 33769463 | Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. | Arch Pathol Lab Med | 2021 |
| 33823167 | Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. | Transplant Cell Ther | 2021 |
| 33601323 | Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. | Eur J Cancer | 2021 |
| 33259934 | Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. | Int J Radiat Oncol Biol Phys | 2021 |
| 33314665 | A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. | Pediatr Blood Cancer | 2021 |